Clover Biopharmaceuticals Co., Ltd. ("Clover Biopharma") and Thousand Oaks Biopharmaceuticals Co., Ltd. announced today the signing of a strategic cooperation agreement on the filling of “S-Trimer”, a COVID-19 recombinant subunit vaccine candidate. The new partnership will further accelerate the progress of the critical Phase II/III clinical effectiveness studies and future commercial manufacturing of Clover Biopharma’s COVID-19 vaccine candidate "S-Trimer” in the world.
As for the "S-trimer” project, Clover Biopharma completed the inoculation of the first group of healthy volunteers in the first-in-human Phase I clinical trial in June this year, released positive pre-clinical data in September, and recently received a funding of up to 328 million US dollars from the Coalition for Epidemic Preparedness Innovations (CEPI). The project is thus highly anticipated by the public. Clover Biopharma will continue to expand its vaccine production scale. It is expected that its production capacity will exceed one billion doses by 2021, to better meet the urgent demand for COVID-19 vaccines from around the world. According to the cooperation agreement, Thousand Oaks Biopharmaceuticals Co., Ltd. will provide fill & finish services for a proportion of the finished products of Clover Biopharma's COVID-19 vaccine project, and spur the progress of the vaccine's crucial Phase II/III clinical trials and future marketing authorization worldwide.
Dr. Peng Liang, Founder and Chairman at Clover Biopharma, and inventor of the Trimer-Tag© (protein trimerization) proprietary technology, said: “It’s exhilarating to reach partnership with Thousand Oaks Biopharmaceuticals Co., Ltd. After having received the additional investment from CEPI, Clover Biopharma is further accelerating the development and clinical research of the COVID-19 subunit vaccine candidate ‘S-Trimer’. The cooperation will help Clover Biopharma speed up the process from clinical trials to commercial manufacturing, so as to provide safe and effective COVID-19 vaccines to the world as soon as possible, and contribute to curbing the COVID-19 pandemic around the globe. "
Dr. Shun Luo, Chairman and President of Thousand Oaks Biopharmaceuticals Co., Ltd., said: "We have been cooperating with Clover Biopharma on various products for years. Its COVID-19 subunit vaccine based on "S-trimer” is highly innovative, and has received extensive attention from the international community. It is our bounden duty to advance the prompt marketing of the vaccine and ensure the supply of raw materials thereafter. We appreciate the trust of Clover Biopharma over the past years! We’ve long wished to play a role in helping our customers and partners with the development of vaccines, providing stable supply of raw materials, shortening the vaccine development cycle and delivering high-quality drug processing capabilities under the premises of safety and compliance, and to make due contributions to the society as a leading technical enterprise."